Grill JD, Flournoy C, Dhadda S, Ernstrom K, et al. Eligibility rates among racially and ethnically diverse US participants in Phase 2 and Phase 3 placebo-controlled, double-blind, randomized trials of lecanemab and elenbecestat in early Alzheimer's disease. Ann Neurol 2023 Oct 13. doi: 10.1002/ana.26819.
PMID: 37830926